Taysha Gene Therapies just emerged out of stealth mode with a $30 million seed round and a strategic partnership with UT Southwestern. The gene therapy-based spinoff specializes in the addressing of diseases caused by a variation in a gene known as monogenic CNS disease. With up to 15 candidates in the pipeline, they are planning up to four investigational new drug (IND) applications.
Who is Taysha Gene Therapies?
Founded in 2020, this brand-new venture is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, they purport to be able to rapidly translate their treatments from bench to bedside. They position their team’s combined experience in gene therapy, drug development and commercialization with the world-class UT Southwestern Gene Therapy Program enabling them to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market infections. Together they leverage their fully integrated platform or what they called an “engine for new cures” to dramatically improve patients’ lives.
Involving previous investors and executives from AveXis (acquired by Novartis), the group has been ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).